Nov 8, 2024

Pricing and reimbursement of multiple indication medicines: Can a balance be found between different stakeholder perspectives to optimise value and access for patients, while ensuring sustainable and affordable innovation?

Share this post

A Dolon Institute report

This report has been developed as part of an ISPOR Europe panel.

Contact us

Whether you're exploring a new opportunity or looking for strategic support, we’d love to hear from you.
Find out more
Contact us

Latest Resources

Explore our latest insights, whitepapers, and event highlights to learn more about the latest developments and perspectives shaping the evolving healthcare landscape.

View all

Get in Touch

Reach out to explore how we can
support your goals

If you're interested in learning more about our services or would like to speak with the team, please get in touch.

Contact us